SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital (APLD) is a top trending stock as investors eagerly await its upcoming earnings report, which is expected to provide critical updates on hyperscaler contracts and the ChronoScale spin-off. The community is buzzing with discussions of a potential short squeeze, fueled by high short interest and recent bullish analyst coverage, as many anticipate strong forward guidance to solidify APLD's position in the rapidly expanding AI infrastructure sector.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing intense trading activity driven by news regarding its blockchain-based Plastic Cycle Token traceability system, which is sparking significant community discussion. Traders are focusing on the stock's exceptionally low share float and high cost to borrow, fueling widespread speculation about a potential short squeeze and significant price expansion.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending due to a notable, prolonged downtrend, surprising many given the broader market's rally, with community members expressing frustration over consistent red days. Traders are actively debating whether the stock is oversold, presenting a buying opportunity, or if concerns about its AI strategy and the Vision Pro's reception signal further weakness. Recent news of JPMorgan reportedly taking over the Apple Credit Card from Goldman Sachs adds to the conversation amid calls for the company to deliver a significant catalyst.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd ($SUGP) is trending due to its ultra-low share float and significant short interest, with community discussion heavily emphasizing its potential for a short squeeze akin to previous explosive moves seen in similar stocks like $SMX. Traders are keenly awaiting upcoming earnings and contract news as potential catalysts, anticipating a breakout above key price levels driven by these strong technical indicators and its presence on the Reg SHO list.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd. is currently trending as community chatter suggests a potential short squeeze, fueled by its ultra-low float, extremely high borrow rates, and inclusion on the Reg SHO list. Traders are actively debating its parabolic upside potential, drawing parallels to previous explosive runners despite skepticism surrounding its underlying fundamentals and "China pump" narratives.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Immuneering Corp

Immuneering (IMRX) is a major talking point after releasing its 12-month overall survival data for atebimetinib in first-line pancreatic cancer, reporting a 64% OS rate. Despite the positive clinical results being described by some as exceptional for this difficult indication, the stock experienced a sharp downturn, leading to intense community debate. Many investors are now evaluating if this price action presents an opportunity to acquire shares in an undervalued company, citing significant institutional interest and the drug's potential.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending due to recent market volatility sparked by political rhetoric concerning potential restrictions on defense contractor dividends and share buybacks, generating widespread community debate over policy intervention. Despite this, investors are also weighing the impact of ongoing strong operational performance, including significant production increases for advanced missile systems and strategic technological partnerships, which underscore the company's long-term defense sector role.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense discussion and price action following a political proposal to ban large institutional investors from home buying. While initially sparking a sell-off, many in the community argue this news is fundamentally bullish, believing Opendoor, as an iBuyer focused on individual homeownership, will benefit from reduced competition and increased transaction opportunities. This has led to strong retail conviction to buy the dip, anticipating a market re-evaluation and potential short squeeze.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

Treasure Global (TGL) is experiencing a surge in trading activity and price movement following news of concluding its equity line facility, which has reduced concerns about future dilution. The community is buzzing with short squeeze speculation, driven by the stock's extremely low float and high cost-to-borrow, drawing comparisons to other recent high-momentum low-float plays.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines (RVMD) is trending sharply lower after AbbVie publicly denied recent media reports of being in advanced talks to acquire the precision oncology company. This denial led to a significant sell-off, with the community expressing frustration over the initial 

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company...

Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $5.00 price target on shares of Plus Therapeutics in a research report on Thursday...

Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Plus Therapeutics in a research report on Monday...

HC Wainwright Expects Weaker Earnings for Plus Therapeutics

Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) - Research analysts at HC Wainwright reduced their FY2027 EPS estimates for shares of Plus Therapeutics in a report issued on Wednesday, November...

What is HC Wainwright's Estimate for PSTV Q1 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Plus Therapeutics in a research note...

Ascendiant Capital Markets Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $19.00

Ascendiant Capital Markets decreased their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday...

&nbsp;November 20, 2025<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.plustherapeutics.com/node/17491/pdf">PDF Version</a>HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-LjgaMRZ499BxpnVFdK1_OIruUYH174LnCXs-fy9J1I_eFQqC3JpTBwOvH766dIT1nH5xLfntIINbP5tEdkB0SDLQG78HFGAOU5BkEJHktWlDyLHpCuy4sMdy9V6Ic4WNMutQlg4-mtVdYtWYaiL2IGkfMeZRCJwGfExniMB_2c8rF2BDTDExok63zegxo0Zzz8pCRIM_zGVoZ1pjMraVCsb47ACHDjHfm535tp8HDAGNMMlGzQxU4v50bSczESWKo6x314ti5HzsTYfN5TjFKj_R0Svs0TsL0Fpuw4o_V2QfDL515ej-QxrOcQDGzj83Xv55B3FzhnQtPM8CwzhHpEEtGvzFWKaNufvlmTXXGcjoyYpySS0ASePbFZjDn0SFCVDnbn2ujI2mvrDFn_YPj4uRtUZKd_u84vRPxhML9hM-8bd2N6am39WyHccsrghDSIS-9PtjI-w5QT1fbwrMTOplD0Zgp5-7lDPMm_u6rKd-HDKnSTsf1VW9kP-ssxp">Plus Therapeutics, Inc.</a>&nbsp;(Nasdaq:&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Qc6X8S3RzScKVxvNu5_ceEM5GEv1Pptj0kvVK2trVYTrKl52rKHptUJcMeFv_r8m6XJ1xYecZnTL9qsMJK-c4D7wONMnr4cOMHuhbyC-B_5ohVVGYSzEJF3Bkl7p1l7wVA64zTIak8hwab7N7Mq556tOQzJlP6kOnE85RNx-iO3w5Wba49-0HAevN_Q0AzurlwzNjWv5cenpZgxc6bFvdrGmTjJRaW_JSEuTLAnXmNlti0LfISAeX284Eg18Lpu6kaosboSHHlT-jVrzzC9bF_XHIR2lKjlwRHyA34hiRVgqvNNrk9BKENa4lSbOz0hxdMgude4ZKO_7LMkYeJ78D5qOqeh8jDUAgckGvzK6XSj4sPM3rAs4MMrV6u79J2HmkaRunbqmC4i9TaFzG2JElk80i-xPqB7Ud8a_0MZs9BXT5C7FRTNYAtbyUh38Wl1-">PSTV</a>) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Ckx5KRl7GkjOTsknevCsv0V8yLayXt9wPOfKjhKbZbbUPUtJYQQ1s_3WMPrcWwJKkvtnm3wVcl2NqQk3TgY1p2feIGsp1Q-lDBhIyjds9Qo=">HUM</a>), effective&nbsp;October 29, 2025, covering approximately 16 million people throughout&nbsp;the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total policy coverage to 67 million people.The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.About CNSide Diagnostics, LLC&nbsp; CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z85jinISrbvcaCeYclceVpAt9mO3Wi78ljN4HTR9BVI1smJG5x77F_beqPHrp5vSTUx_fkwpPQaECwHXeOdYGN4=">https://www.cnside-dx.com/</a>.About Plus Therapeutics Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z35nW-kNODbXQZtlDECdtGDGWCcawXezTzcic5Wa0-GT7YTxFESUvgVo1SXipvsyvJqzICHTRIfUoONu9xOH9uwwt2yHEFxsHOOelgYY9iSs">https://www.plustherapeutics.com</a>.About HumanaHumana Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=sVqa190sv-OGip6yFjYGO0t_cm6VKwY3aysRDxYxSjt0DTCbL2OqMK2Oz0V0BVN0kxVxe1yu5iCIPHAl4xJijJT_ANoSx8Di9opJClAXJ3U=">HUM</a>) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.Forward-Looking Statements This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.Investor Contact CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investor@plustherapeutics.com">investor@plustherapeutics.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

CNSide Diagnostics, a Plus Therapeutics subsidiary, secured a national agreement with Humana to provide its CNSide CSF Tumor Cell Enumeration test, expanding coverage to 67 million people.

Others

Plus Therapeutics (NASDAQ:PSTV) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $5.00 target price on shares of Plus Therapeutics in a research note on Thursday...

Plus Therapeutics (NASDAQ:PSTV) Downgraded to "Hold" Rating by Zacks Research

Zacks Research lowered shares of Plus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday...

Plus Therapeutics (NASDAQ:PSTV) CFO Andrew John Hugh Macintyr Sims Buys 20,000 Shares

Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) CFO Andrew John Hugh Macintyr Sims acquired 20,000 shares of the firm's stock in a transaction on Tuesday, November 4th. The shares were bought...

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Plus Therapeutics Inc

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

Current Price	$0.6078
Prev Close	$0.561
Open	$0.57
Dividend Yield	0.00%
50-Day Moving Average	$0.5718
Beta	1.28
Avg. Volume	4.55M
PE Ratio	-0.29

52-Week High	$2.31
52-Week Low	$0.1634
Market Capitalization	$77.24M
EPS (Annual)	-$2.34
Price to Book	14.61
Revenue Per Employee	$277,333.33
Enterprise Value/EBITDA	N/A

PSTV
Plus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSTV News

PSTVPlus Therapeutics Inc